[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:cd5-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"CD5 Gene",5,4,[8,16,23,30,36],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07321652","Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL\u002FSLL",[12],"Phase 3","RECRUITING","2026-08-26T02:19:14.560989Z","2026-06-17T02:29:30.059389Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06846463","Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+",[20],"Phase 2","2026-08-26T02:19:13.549512Z","2026-05-05T02:43:28.810232Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06420089","CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)",[27],"Phase 1","2026-08-26T02:18:11.042248Z","2026-05-05T02:43:27.338830Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT03081910","Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen",[27],"2026-08-26T02:18:57.189473Z","2026-05-05T02:43:26.923493Z",{"nct_id":37,"title":38,"phases":39,"status":40,"updated_at":41,"content_modified":42},"NCT07137481","Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies",[20],"NOT_YET_RECRUITING","2026-08-26T02:19:17.380174Z","2026-05-05T02:43:28.805067Z"]